Loading stock data…
$11.50-0.02 (-0.17%)
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications.
Enanta Pharmaceuticals, Inc. in the Healthcare sector is trading at $11.50 with a market capitalization of $335M. Wall Street consensus targets $21.83 (6 analysts), implying a +89.9% move over the next 12 months. The stock is currently near its 52-week low of $10.20, remaining 13.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $14.36M↓ | $17.16M↓ | $18.61M↑ | $15.13M↓ | $18.31M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$17.24M↓ | -$11.85M↓ | -$11.25M↑ | -$18.39M↑ | -$18.89M |
| Net Income | -$19.50M↓ | -$13.09M↓ | -$11.94M↑ | -$18.70M↓ | -$18.25M |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment ...